YYÜ GCRIS Basic veritabanının içerik oluşturulması ve kurulumu Research Ecosystems (https://www.researchecosystems.com) tarafından devam etmektedir. Bu süreçte gördüğünüz verilerde eksikler olabilir.
 

The Effect of Different Doses of Isotretinoin on Pituitary Hormones

dc.authorid Takci, Zennure/0000-0001-7257-5792
dc.authorscopusid 26425048800
dc.authorscopusid 55257710400
dc.authorscopusid 9280148200
dc.authorscopusid 17134049200
dc.authorscopusid 6507988055
dc.authorscopusid 14520105500
dc.authorwosid Takci, Zennure/Aaa-1069-2020
dc.authorwosid Karadag, Ayse/V-7974-2018
dc.contributor.author Karadag, Ayse Serap
dc.contributor.author Takci, Zennure
dc.contributor.author Ertugrul, Derun Taner
dc.contributor.author Bilgili, Serap Gunes
dc.contributor.author Balahoroglu, Ragip
dc.contributor.author Takir, Mumtaz
dc.date.accessioned 2025-05-10T17:42:22Z
dc.date.available 2025-05-10T17:42:22Z
dc.date.issued 2015
dc.department T.C. Van Yüzüncü Yıl Üniversitesi en_US
dc.department-temp [Karadag, Ayse Serap] Istanbul Medeniyet Univ, Goztepe Res & Training Hosp, Sch Med, Dept Dermatol, TR-34722 Istanbul, Turkey; [Takir, Mumtaz] Istanbul Medeniyet Univ, Goztepe Res & Training Hosp, Sch Med, Dept Endocrinol, TR-34722 Istanbul, Turkey; [Takci, Zennure] Gaziosmanpasa Univ, Sch Med, Dept Dermatol, Tokat, Turkey; [Ertugrul, Derun Taner] Kecioren Res & Training Hosp, Dept Endocrinol, Ankara, Turkey; [Bilgili, Serap Gunes; Balahoroglu, Ragip] Yuzuncu Yil Univ, Sch Med, Dept Dermatol, Van, Turkey en_US
dc.description Takci, Zennure/0000-0001-7257-5792 en_US
dc.description.abstract Background: There are a limited number of studies investigating the side effects and effectiveness of various doses of isotretinoin (ISO). We have previously shown that high-dose ISO affects pituitary hormones. Objectives: To our knowledge, there is no study in the literature looking into the effects of various doses of ISO on pituitary hormones. We searched pituitary hormones in three groups of different doses in acne patients. Methods: We included 105 acne vulgaris patients from two different centers. We divided the patients into three groups; the first group received 0.5-1 mg/kg/day, the second 0.2-0.5 mg/kg/day and the third intermittent 0.5-1 mg/kg/day (only 1 week in 1 month) ISO treatment. Blood samples were collected for biochemistry and hormone analysis, before the treatment and after 3 months. Results: After 3 months of treatment with ISO, luteinizing hormone (LH) (p < 0.001), prolactin (p < 0.001), total testosterone (p < 0.001), adrenocorticotropic hormone (ACTH) (p < 0.001), cortisol (p < 0.001), insulin-like growth factor-binding protein 3 (p < 0.001), insulin-like growth factor 1 (IGF-1) (p = 0.002), growth hormone (GH) (p = 0.002) and free T3 (fT3) (p < 0.001) levels had decreased significantly. Furthermore, we split data into three different groups. Among the patients receiving intermittent-dose ISO, LH, ACTH, IGF-1, GH and fT3 measurements lost significance. Most of the significant measurements observed in the whole group were also significant among the patients receiving high-dose ISO. Additionally, dehydroepiandrosterone sulfate (p = 0.003) levels increased, and free T4 levels decreased significantly. Conclusions: ISO affects pituitary hormones at all of these three doses. The differences in pituitary hormones are more pronounced in high-dose treatment. The weakest effect was observed in the intermittent-dose group. Choosing lower doses of ISO may decrease side effects, however the effectiveness of the treatment may also be diminished. ISO, by affecting the PPAR gamma/RXR system, may affecting hormone systems. These changes in various hormone systems may be related to the effectiveness of ISO. (C) 2015 S. Karger AG, Basel en_US
dc.description.sponsorship Turkish Dermatology Association Scientific Research Project en_US
dc.description.sponsorship This project was supported by Turkish Dermatology Association Scientific Research Project September 2011. en_US
dc.description.woscitationindex Science Citation Index Expanded
dc.identifier.doi 10.1159/000375370
dc.identifier.endpage 359 en_US
dc.identifier.issn 1018-8665
dc.identifier.issn 1421-9832
dc.identifier.issue 4 en_US
dc.identifier.pmid 25721216
dc.identifier.scopus 2-s2.0-84929951394
dc.identifier.scopusquality Q1
dc.identifier.startpage 354 en_US
dc.identifier.uri https://doi.org/10.1159/000375370
dc.identifier.uri https://hdl.handle.net/20.500.14720/15516
dc.identifier.volume 230 en_US
dc.identifier.wos WOS:000354004000012
dc.identifier.wosquality Q2
dc.language.iso en en_US
dc.publisher Karger en_US
dc.relation.publicationcategory Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı en_US
dc.rights info:eu-repo/semantics/closedAccess en_US
dc.subject Isotretinoin en_US
dc.subject Pituitary Hormones en_US
dc.title The Effect of Different Doses of Isotretinoin on Pituitary Hormones en_US
dc.type Article en_US

Files